CompletedNot applicableNCT00096850

Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults

Studying Primary genito-urinary tuberculosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator
David W. Haas, MD, M.D
Infectious Diseases, Vanderbilt University Medical Center
Intervention
Atazanavir(drug)
Enrollment
18 enrolled
Eligibility
18-55 years · All sexes
Timeline
2007

Study locations (3)

Collaborators

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00096850 on ClinicalTrials.gov

Other trials for Primary genito-urinary tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Primary genito-urinary tuberculosis

← Back to all trials